What are the most important things to know about Delstrigo?
Delstrigo may cause side effects. These include kidney problems, including kidney failure, and bone problems, such as bone pain or bone softening or thinning (which may lead to broken bones).Contact your health care provider right away if you have any of the following symptoms that could be signs of a kidney or bone problem:
- Bone pain that does not go away or gets worse
- Pain in your arms, legs, hands, or feet
- Broken bones
- Muscle pain or weakness
If you have both HIV and(HBV) and take Delstrigo, your HBV may get much worse (flare up) if you stop taking Delstrigo. Do not stop taking Delstrigo without first talking to your health care provider.
While taking Delstrigo, it is important to keep all of your appointments with your health care provider.
What is Delstrigo?
Delstrigo is a prescription medicine approved by the U.S.(FDA) for the treatment of HIV infection in adults who have never taken HIV medicines before. Delstrigo has also been approved to replace the current in adults who meet certain requirements, as determined by a health care provider.
Delstrigo is a complete regimen for the treatment of HIV infection and should not be used with other HIV medicines.
HIV medicines can’t cure HIV/AIDS, but taking HIV medicines every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV. If you are taking HIV medicines, don’t cut down on, skip, or stop taking them unless your health care provider tells you to.
What should I tell my health care provider before taking Delstrigo?
Before taking Delstrigo, tell your health care provider:
- If you are allergic to any of the HIV medicines in Delstrigo (doravirine, lamivudine, or tenofovir disoproxil fumarate) or any other medicines.
- If you have B infection (HBV).
- If you have kidney problems.
- If you have bone problems, including a history of brokenbones.
- If you have any other medical conditions.
- If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of taking Delstrigo during pregnancy.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV or are taking Delstrigo.
- If you are using HIV and Birth Control infographic. -based birth control (such as pills, implants, or vaginal rings). For more information about using birth control and HIV medicines at the same time, view the
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products (particularly St. John's wort) you are taking or plan to take. Delstrigo may affect the way other medicines or products work, and other medicines or products may affect how Delstrigo works. Taking Delstrigo together with certain medicines or products may cause life-threatening side effects.
How should I take Delstrigo?
Delstrigo comes in tablet form. Each tablet contains:
- 100 mg doravirine (brand name: Pifeltro)
- 300 mg lamivudine (brand name: Epivir)
- 300 mg tenofovir disoproxil fumarate (brand name: Viread)
Take Delstrigo according to your health care provider’s instructions.
Delstrigo can be taken with or without food.
If you also take the medicine rifabutin during treatment with Delstrigo, you may not have enough doravirine in your blood. (Doravirine is one of the medicines in Delstrigo.) Your health care provider will prescribe an additional of doravirine for you to take. Follow your health care provider’s instructions about when to take doravirine and how much to take. This is usually one tablet of doravirine about 12 hours after your last dose of Delstrigo.
If you take too much Delstrigo, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room.
For more information on how to take Delstrigo, see the FDA drug label.
What should I do if I forget a dose?
If you miss a dose of Delstrigo, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
What side effects can Delstrigo cause?
Delstrigo may cause side effects. Many side effects from HIV medicines, such as nausea or occasional dizziness, are manageable. See the ClinicalInfo fact sheet on HIV Medicines and Side Effects for more information.
Some side effects of Delstrigo can be serious. Serious side effects of Delstrigo include kidney and bone problems. (See section above: What are the most important things to know about Delstrigo?)
Another possible side effect of Delstrigo is changes in your(called or IRIS). IRIS is a condition that sometimes occurs when the immune system begins to recover after treatment with an HIV medicine. As the immune system gets stronger, it may have an increased response to a previously hidden infection.
Tell your health care provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Delstrigo. To learn more about possible side effects of Delstrigo, read the drug label oror talk to your health care provider or pharmacist.
You can report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or online.
How should Delstrigo be stored?
- Store Delstrigo at room temperature, 68°F to 77°F (20°C to 25°C).
- Keep Delstrigo in the container that it came in and keep the container tightly closed. If the container has a small packet of drying agent (called a desiccant), do not remove it. The desiccant protects the medicine from moisture.
- Do not use Delstrigo if the original seal over the container opening is broken or missing.
- Throw away Delstrigo that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep Delstrigo and all medicines out of reach of children.
Where can I find more information about Delstrigo?
More information about Delstrigo is available:
Merck & Co., Inc.
Main number: 877-888-4231
Patient assistance: 800-727-5400
The above Patient Version drug summary is based on the following FDA label(s): Tablet (film-coated).
Last Reviewed: August 30, 2019